Browse Category

NYSE:ABT News 7 July 2025 - 15 October 2025

Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Abbott (ABT) Stock Slides on Mixed Q3 Results – Is a Rally Over?

Price and Performance Abbott’s stock has been trading in a tight range around $128–$133 in mid-October 2025. On Oct 15, the price was about $128 – down 3.5% intraday reuters.com. Over the past few trading days ABT fell from $131.38 (Oct 13 close) and $133.27 (Oct 14) to $128.77 stockanalysis.com. In context, ABT’s YTD gain is roughly 18%, outpacing the broad market. (By comparison, the S&P 500 is up ~13% YTD nasdaq.com.) The stock’s forward P/E is about 24–25 (slightly lower than a few months ago) tradingview.com, suggesting analysts see modest growth ahead. Q3 Results and Guidance Abbott’s Q3 earnings
Global Wearable Health Tech News – June and July 2025

Global Wearable Health Tech News – June and July 2025

Biobeat’s cuffless vital-sign patch received FDA clearance and CE marking for hospital-grade remote monitoring, enabling cuffless measurement of blood pressure, heart rate, SpO2, and respiratory rate via PPG and AI. On June 19, PharmaSens and SiBionics announced niia™ signature, an all-in-one patch that combines a continuous glucose monitor with an insulin pump, unveiled at ADA 2025. LifePlus’s LifeLeaf non-invasive monitor (June 24) is a cuffless device for continuous glucose and blood pressure tracking, validated in Mayo Clinic trials with readings within about 10.8% of glucometers and BP error around 0.03 mmHg. Wearable Devices Ltd.’s Large-Motion AI Platform expansion on June
Go toTop